Key result
Chronic use of aspirin was associated with reduced 24-month all-cause mortality in patients undergoing planned peripheral vascular reconstruction, with zero deaths among aspirin users.
Why the study?
Does chronic use of aspirin reduce mortality in patients with symptomatic peripheral arterial disease undergoing planned peripheral vascular reconstruction?
Observational (n=75)
Does chronic use of aspirin reduce mortality in patients with symptomatic peripheral arterial disease undergoing planned peripheral vascular reconstruction?
Answers are grounded in this paper and cite their sources.
In patients with symptomatic peripheral arterial disease undergoing planned peripheral vascular reconstruction, chronic use of aspirin is associated with significantly reduced all-cause mortality.
INTRODUCTION: The present study examines cardiovascular risk factor profiles and 24-month mortality in patients with symptomatic peripheral arterial disease. DESIGN STUDY: Prospective observational study including 75 consecutive patients with PAD (67 +/- 9.7 years of age; 52 men and 23 women) hospitalized for planned peripheral vascular reconstruction. Doppler echocardiograms were performed before surgery in 54 cases. Univariate analyses were performed using Student's t-test or Fisher's exact test. Survival analysis at 24-month follow-up was performed using the Cox regression model and Kaplan-Meier method including age and chronic use of aspirin as covariates. Survival curves were compared using the log-rank test. RESULTS: Hypertension and smoking were the most frequent risk factors (52 cases and 51 cases, respectively), followed by diabetes (32 cases). Undertreated dyslipidemia was found in 26 cases. Fasting glycine levels (131 +/- 69.1 mg/dl) were elevated in 29 cases. Myocardial hypertrophy was found in 18 out of 54 patients. Thirty-four patients had been treated with aspirin. Overall mortality over 24 months was 24% and was associated with age (HR: 0.064; CI95: 0.014-0.115; p=0.013) and lack of use of aspirin, as no deaths occurred among those using this drug (p<0.001). No association was found between cardiovascular death (11 cases) and the other risk factors. CONCLUSION: There is a high prevalence of uncontrolled (treated or untreated) cardiovascular risk factors in patients undergoing planned peripheral vascular reconstruction, and chronic use of aspirin is associated with reduced all-cause mortality in these patients.
No takes yet. Share an insight, caveat, or question.
Bazan et al. (2009) conducted an observational in Symptomatic peripheral arterial disease (n=75). Chronic use of aspirin vs. Lack of use of aspirin was evaluated on Overall mortality over 24 months (p=<0.001). Chronic use of aspirin was associated with reduced 24-month all-cause mortality in patients undergoing planned peripheral vascular reconstruction, with zero deaths among aspirin users.
Synapse has enriched 10 related papers. Consider them for comparative context: